ReShape Common Stock vs Accounts Payable Analysis

RSLS Stock

USD 0.25 0.03 10.71%

ReShape Lifesciences financial indicator trend analysis is much more than just breaking down ReShape Lifesciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ReShape Lifesciences is a good investment. Please check the relationship between ReShape Lifesciences Common Stock and its Accounts Payable accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

Common Stock vs Accounts Payable

Common Stock vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ReShape Lifesciences Common Stock account and Accounts Payable. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between ReShape Lifesciences' Common Stock and Accounts Payable is -0.57. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of ReShape Lifesciences, assuming nothing else is changed. The correlation between historical values of ReShape Lifesciences' Common Stock and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of ReShape Lifesciences are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Common Stock i.e., ReShape Lifesciences' Common Stock and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.57

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Common Stock

Accounts Payable

An accounting item on the balance sheet that represents ReShape Lifesciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of ReShape Lifesciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from ReShape Lifesciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ReShape Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.At this time, ReShape Lifesciences' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.20 in 2024, whereas Tax Provision is likely to drop (36.8 K) in 2024.

ReShape Lifesciences fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets	Short Term Debt
Total Assets		0.97	-0.13	0.73	-0.31	0.34	0.57	-0.12	-0.31	0.15	0.23	-0.3	0.34	0.21	0.92	0.37	-0.18	0.2	0.25	0.12	0.44	0.09	0.17	-0.31	0.26	0.22
Total Stockholder Equity	0.97		-0.13	0.8	-0.24	0.31	0.37	-0.16	-0.43	0.0	0.21	-0.32	0.27	0.21	0.9	0.42	-0.19	0.2	0.19	0.09	0.34	0.07	0.15	-0.23	0.26	0.18
Retained Earnings	-0.13	-0.13		0.08	-0.48	-0.91	-0.08	0.73	0.02	-0.39	-0.31	-0.22	-0.69	0.47	-0.17	0.25	-0.5	0.47	-0.73	0.52	0.42	-0.02	-0.4	0.51	0.19	0.3
Other Assets	0.73	0.8	0.08		-0.15	0.05	0.11	-0.18	-0.5	-0.37	-0.12	-0.08	-0.09	0.0	0.78	0.29	-0.37	-0.01	-0.14	0.16	0.44	-0.14	-0.14	-0.06	-0.03	0.01
Common Stock Shares Outstanding	-0.31	-0.24	-0.48	-0.15		0.2	-0.4	-0.23	-0.16	-0.09	-0.14	0.1	-0.06	-0.19	-0.31	-0.4	0.42	-0.18	0.04	-0.19	-0.48	-0.33	-0.11	-0.13	0.02	-0.28
Other Stockholder Equity	0.34	0.31	-0.91	0.05	0.2		0.24	-0.67	-0.02	0.39	0.36	0.13	0.76	-0.37	0.35	-0.1	0.4	-0.37	0.78	-0.43	-0.25	0.11	0.44	-0.51	-0.17	-0.19
Total Liab	0.57	0.37	-0.08	0.11	-0.4	0.24		0.09	0.3	0.62	0.18	-0.07	0.42	0.1	0.49	0.0	-0.02	0.1	0.35	0.17	0.59	0.12	0.13	-0.41	0.11	0.27
Short Long Term Debt Total	-0.12	-0.16	0.73	-0.18	-0.23	-0.67	0.09		-0.06	-0.08	-0.21	-0.19	-0.55	0.55	-0.23	0.1	-0.02	0.55	-0.53	0.47	0.38	-0.23	-0.26	0.42	0.35	0.54
Other Current Liab	-0.31	-0.43	0.02	-0.5	-0.16	-0.02	0.3	-0.06		0.41	0.44	-0.33	0.19	0.26	-0.48	-0.16	0.1	0.26	0.24	0.17	-0.04	0.09	0.45	-0.2	0.29	-0.47
Total Current Liabilities	0.15	0.0	-0.39	-0.37	-0.09	0.39	0.62	-0.08	0.41		0.41	0.02	0.62	-0.05	0.09	-0.36	0.44	-0.04	0.62	-0.34	-0.15	0.09	0.41	-0.25	0.11	-0.04
Property Plant And Equipment Net	0.23	0.21	-0.31	-0.12	-0.14	0.36	0.18	-0.21	0.44	0.41		-0.47	0.57	0.31	0.06	0.11	0.55	0.31	0.58	-0.18	-0.08	-0.02	0.98	0.03	0.48	-0.51
Net Debt	-0.3	-0.32	-0.22	-0.08	0.1	0.13	-0.07	-0.19	-0.33	0.02	-0.47		0.2	-0.92	0.09	-0.5	0.06	-0.93	0.19	-0.49	0.05	0.01	-0.4	0.23	-0.95	0.08
Accounts Payable	0.34	0.27	-0.69	-0.09	-0.06	0.76	0.42	-0.55	0.19	0.62	0.57	0.2		-0.38	0.4	-0.19	0.39	-0.38	0.96	-0.57	-0.09	0.35	0.56	-0.21	-0.18	-0.31
Cash	0.21	0.21	0.47	0.0	-0.19	-0.37	0.1	0.55	0.26	-0.05	0.31	-0.92	-0.38		-0.16	0.47	-0.06	1.0	-0.36	0.6	0.11	-0.1	0.24	-0.03	0.94	0.15
Non Current Assets Total	0.92	0.9	-0.17	0.78	-0.31	0.35	0.49	-0.23	-0.48	0.09	0.06	0.09	0.4	-0.16		0.19	-0.19	-0.16	0.3	-0.09	0.49	0.09	0.02	-0.14	-0.12	0.21
Non Currrent Assets Other	0.37	0.42	0.25	0.29	-0.4	-0.1	0.0	0.1	-0.16	-0.36	0.11	-0.5	-0.19	0.47	0.19		-0.43	0.45	-0.31	0.4	0.09	0.42	0.02	-0.3	0.37	0.27
Long Term Debt	-0.18	-0.19	-0.5	-0.37	0.42	0.4	-0.02	-0.02	0.1	0.44	0.55	0.06	0.39	-0.06	-0.19	-0.43		-0.07	0.45	-0.49	-0.23	-0.33	0.61	0.21	0.12	-0.32
Cash And Short Term Investments	0.2	0.2	0.47	-0.01	-0.18	-0.37	0.1	0.55	0.26	-0.04	0.31	-0.93	-0.38	1.0	-0.16	0.45	-0.07		-0.36	0.6	0.1	-0.1	0.24	-0.03	0.94	0.15
Net Receivables	0.25	0.19	-0.73	-0.14	0.04	0.78	0.35	-0.53	0.24	0.62	0.58	0.19	0.96	-0.36	0.3	-0.31	0.45	-0.36		-0.55	-0.16	0.17	0.61	-0.19	-0.14	-0.38
Common Stock Total Equity	0.12	0.09	0.52	0.16	-0.19	-0.43	0.17	0.47	0.17	-0.34	-0.18	-0.49	-0.57	0.6	-0.09	0.4	-0.49	0.6	-0.55		0.39	-0.24	-0.23	-0.22	0.45	0.36
Non Current Liabilities Total	0.44	0.34	0.42	0.44	-0.48	-0.25	0.59	0.38	-0.04	-0.15	-0.08	0.05	-0.09	0.11	0.49	0.09	-0.23	0.1	-0.16	0.39		-0.14	-0.13	0.16	-0.05	0.3
Other Current Assets	0.09	0.07	-0.02	-0.14	-0.33	0.11	0.12	-0.23	0.09	0.09	-0.02	0.01	0.35	-0.1	0.09	0.42	-0.33	-0.1	0.17	-0.24	-0.14		-0.09	-0.27	-0.11	0.11
Property Plant And Equipment Gross	0.17	0.15	-0.4	-0.14	-0.11	0.44	0.13	-0.26	0.45	0.41	0.98	-0.4	0.56	0.24	0.02	0.02	0.61	0.24	0.61	-0.23	-0.13	-0.09		0.01	0.41	-0.54
Preferred Stock Total Equity	-0.31	-0.23	0.51	-0.06	-0.13	-0.51	-0.41	0.42	-0.2	-0.25	0.03	0.23	-0.21	-0.03	-0.14	-0.3	0.21	-0.03	-0.19	-0.22	0.16	-0.27	0.01		-0.16	-0.11
Total Current Assets	0.26	0.26	0.19	-0.03	0.02	-0.17	0.11	0.35	0.29	0.11	0.48	-0.95	-0.18	0.94	-0.12	0.37	0.12	0.94	-0.14	0.45	-0.05	-0.11	0.41	-0.16		0.0
Short Term Debt	0.22	0.18	0.3	0.01	-0.28	-0.19	0.27	0.54	-0.47	-0.04	-0.51	0.08	-0.31	0.15	0.21	0.27	-0.32	0.15	-0.38	0.36	0.3	0.11	-0.54	-0.11	0.0

Click cells to compare fundamentals

ReShape Lifesciences Account Relationship Matchups

ReShape Lifesciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	39.7M	37.1M	54.3M	11.1M	10.7M	10.2M
Total Stockholder Equity	24.1M	14.5M	46.1M	3.7M	6.7M	6.3M
Retained Earnings	(493.2M)	(514.8M)	(576.8M)	(624.2M)	(635.6M)	(603.8M)
Other Assets	99K	46K	1.5M	102K	117.3K	111.4K
Common Stock Shares Outstanding	31.4K	26.0K	218.5K	424.4K	6.0M	6.3M
Liabilities And Stockholders Equity	39.7M	37.1M	54.3M	11.1M	10.7M	10.2M
Other Stockholder Equity	517.3M	529.4M	622.9M	627.9M	642.3M	323.4M
Total Liab	15.6M	22.6M	8.2M	7.5M	4.1M	3.9M
Short Long Term Debt Total	768K	477K	279K	171K	262K	248.9K
Other Current Liab	5.6M	7.2M	3.0M	4.9M	1.3M	1.3M
Total Current Liabilities	10.4M	11.6M	7.3M	7.5M	3.8M	6.0M
Property Plant And Equipment Net	774K	1.0M	1.7M	869K	310K	600.4K
Net Debt	(2.2M)	(2.5M)	(22.5M)	(3.7M)	(4.3M)	(4.5M)
Accounts Payable	4.3M	3.7M	3.5M	1.9M	1.7M	1.3M
Cash	2.9M	3.0M	22.8M	3.9M	4.6M	4.3M
Non Current Assets Total	29.5M	28.1M	24.0M	1.2M	431K	409.5K
Non Currrent Assets Other	562.9K	99K	46K	1.5M	29K	27.6K
Cash And Short Term Investments	2.9M	3.0M	22.8M	3.9M	4.6M	4.3M
Net Receivables	4.1M	2.6M	2.8M	2.2M	1.7M	997.2K
Non Current Liabilities Total	5.2M	11.0M	855K	2.6M	287.0K	272.6K
Other Current Assets	1.7M	1.1M	1.6M	84K	337K	320.2K
Property Plant And Equipment Gross	774K	1.0M	1.7M	1.2M	400K	618.1K
Total Current Assets	10.1M	8.9M	30.3M	9.9M	10.3M	16.2M
Accumulated Other Comprehensive Income	(8K)	(121K)	(92K)	(88K)	(79.2K)	(83.2K)
Short Term Debt	291K	314K	279K	171K	111K	105.5K
Common Stock	8K	6K	18K	1K	23K	21.9K
Property Plant Equipment	16K	584K	1.7M	869K	782.1K	565.6K
Other Liab	6.2M	4.7M	1.6M	855K	983.3K	934.1K
Current Deferred Revenue	352K	202K	398K	549K	639K	671.0K
Inventory	1.3M	2.2M	3.0M	3.6M	3.7M	3.9M
Net Tangible Assets	(4.6M)	(12.5M)	25.2M	3.4M	3.1M	4.0M
Retained Earnings Total Equity	(334.8M)	(419.0M)	(493.2M)	(514.8M)	(463.3M)	(486.5M)
Capital Surpluse	410.8M	450.6M	517.3M	529.4M	608.8M	386.1M
Deferred Long Term Liab	5.3M	1.8M	702K	615K	707.3K	929.9K
Intangible Assets	28.7M	27.0M	20.8M	260K	299K	284.1K

Pair Trading with ReShape Lifesciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ReShape Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ReShape Lifesciences will appreciate offsetting losses from the drop in the long position's value.

Moving against ReShape Stock

0.53	WST	West Pharmaceutical	Pair Corr
0.44	SSY	SunLink Health Systems	Pair Corr
0.43	FNA	Paragon 28	Pair Corr
0.41	CAH	Cardinal Health Fiscal Year End 20th of August 2024	Pair Corr

The ability to find closely correlated positions to ReShape Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ReShape Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ReShape Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ReShape Lifesciences to buy it.

The correlation of ReShape Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ReShape Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ReShape Lifesciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ReShape Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether ReShape Lifesciences is a strong investment it is important to analyze ReShape Lifesciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ReShape Lifesciences' future performance. For an informed investment choice regarding ReShape Stock, refer to the following important reports:

How To Invest In ReShape

Details

Is ReShape Stock a good investment?

Details

What is ReShape Lifesciences' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Complementary Tools for ReShape Stock analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.

	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Global Correlations Find global opportunities by holding instruments from different markets
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio

Is ReShape Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ReShape Lifesciences. If investors know ReShape will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ReShape Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.44)

Revenue Per Share

0.732

Quarterly Revenue Growth

(0.15)

Return On Assets

(0.57)

Return On Equity

(1.78)

The market value of ReShape Lifesciences is measured differently than its book value, which is the value of ReShape that is recorded on the company's balance sheet. Investors also form their own opinion of ReShape Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is ReShape Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ReShape Lifesciences' market value can be influenced by many factors that don't directly affect ReShape Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ReShape Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ReShape Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ReShape Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ReShape Common Stock vs Accounts Payable Analysis

Common Stock vs Accounts Payable

Common Stock vs Accounts Payable Correlation Analysis

Correlation Coefficient

Common Stock

Accounts Payable

ReShape Lifesciences fundamental ratios Correlations

ReShape Lifesciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ReShape Lifesciences fundamental ratios Accounts

Pair Trading with ReShape Lifesciences

Moving against ReShape Stock

Complementary Tools for ReShape Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.97	Total Assets
Net Receivables	+ 0.96	Accounts Payable
Total Current Assets	+ 0.94	Cash
Total Current Assets	+ 0.94	Cash And Short Term Investments

Total Current Assets	- 0.95	Net Debt
Cash And Short Term Investments	- 0.93	Net Debt
Cash	- 0.92	Net Debt
Other Stockholder Equity	- 0.91	Retained Earnings
Net Receivables	- 0.73	Retained Earnings
Accounts Payable	- 0.69	Retained Earnings